EHA 2016 – Leukemia

5-Azacitidine plus Checkpoint Inhibitor May Enhance Outcomes in Patients with De Novo and Relapsed AML

EHA 2016 – Leukemia, EHA

Conference Correspondent

Acalabrutinib, a Second-Generation BTK Inhibitor, Is Active in Previously Untreated CLL

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

ALL – Clinical Oral Presentations: Saturday, June 11

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

ALL – Clinical Poster Session: Friday, June 10

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Blinatumomab Demonstrates Overall Survival Benefit in Adults with Relapsed ALL in the TOWER Study

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

CD19 CAR T Cells Induce Potent Responses and Control CNS Leukemia in Relapsed ALL

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

CLL – Clinical Poster Session: Friday, June 10

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Duration of TKI Treatment and Duration of Deep Molecular Response Affect Relapse-Free Survival in CML

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Higher-Dose Daunorubicin Is Effective in Patients with AML Who Harbor FLT3-ITD Mutations

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Ibrutinib plus Bendamustine and Rituximab (BR) in Previously Treated CLL/SLL: 2-Year Follow-Up Data from the HELIOS Study

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent

Page 1 of 2

1
2